Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Insomnia Disorder

In brief

This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.

Key facts

Study ID

NCT02839200

Run by

Idorsia Pharmaceuticals Ltd.

People needed

360

Starts

2016-10-04

Expected to finish

2017-06-20

Last updated by the study team

2020-04-13

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigator Site — Santa Monica, California, United States
• Investigator Site — Upland, California, United States
• Investigator Site — Brandon, Florida, United States
• Investigator Site — Clearwater, Florida, United States
• Investigator Site — Coral Gables, Florida, United States
• Investigator Site — DeLand, Florida, United States
• Investigator Site — Hollywood, Florida, United States
• Investigator Site — Miami, Florida, United States
• Investigator Site — Atlanta, Georgia, United States
• Investigator Site — Chicago, Illinois, United States
• Investigator Site — Indianapolis, Indiana, United States
• Investigator Site — Novi, Michigan, United States
• Investigator Site — Las Vegas, Nevada, United States
• Investigator Site — New York, New York, United States
• Investigator Site — Cincinnati, Ohio, United States
• Investigator Site — Berlin, Germany
• Investigator Site — Berlin, Germany
• Investigator Site — Berlin, Germany
• Investigator Site — Dresden, Germany
• Investigator Site — Hamburg, Germany
• Investigator Site — Hamburg, Germany
• Investigator Site — Hanover, Germany
• Investigator Site — Schwerin, Germany
• Investigator Site — Schwerin, Germany
• Investigator Site — Budapest, Hungary

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.